Project Grant R21HL189039
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $233K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Duke University $238,516 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct admixture mapping of genetic modifiers in sickle cell disease. The research leverages the National Heart, Lung, and Blood Institute's TOPMed program, which includes multiple cross-sectional adult sickle cell disease cohorts totaling more than 4,000 participants with whole genome sequencing data and extensive clinical...
- The National Heart, Lung, and Blood Institute awarded The University of North Texas Health Science Center at Fort Worth $426,550 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a bioengineering modular gene delivery system for lung-targeted transgene expression. The project addresses systemic gene therapy for monogenic lung diseases including cystic fibrosis, alpha-1-antitrypsin deficiency, and pulmonary arterial hypertension. The recipient...
- The National Heart, Lung, and Blood Institute awarded the University of California Irvine $235,500 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to examine familial hypercholesterolemia prevalence, underdiagnosis, and undertreatment disparities in the United States. The recipient will analyze whole genome sequencing and electronic health record data to characterize the current state of familial hypercholesterolemia (FH) across demographic variables,...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $773,466 under the Cardiovascular Diseases Research program (CFDA 93.837) on July 3, 2026, to investigate CXCL5-CXCR2 signaling mechanisms in macrophage cholesterol efflux and atherosclerosis prevention. The research integrates systems biology, pharmacology, and atherosclerosis expertise across three aims: elucidating CXCL5-CXCR2 signaling mechanisms using multi-omics and CRISPR-Cas9 in human...
- The National Heart Lung and Blood Institute awarded the University of North Carolina at Chapel Hill $777,419 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the muco-obstructive mechanisms underlying bronchiectasis and identify novel therapeutic targets. The research examines bronchiectasis pathogenesis through a revised conceptual model that integrates airway epithelial hypoxia, mucus hyperconcentration, osmotic pressure-driven airway...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $441,375 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 15, 2025, with completion targeted for July 31, 2027. The award funds research to develop and optimize a dual adeno-associated virus (AAV) gene delivery system employing intein technology to deliver full-length, functional cystic fibrosis transmembrane...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $546,054 on August 24, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct basic research on chromatin remodeling and histone chaperone function in cardiomyocyte maturation. The project investigates how chromatin architecture and localized nucleosome remodeling cooperate to drive cardiomyocyte maturation during the fetal-to-adult transition. The research focuses...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $171,488 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a nationwide examination of access to comprehensive care in sickle cell disease. The research uses national Medicaid insurance claims data to address two analytic aims. The first aim identifies three groups of people with sickle cell disease—those who do not receive care from a...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $2.31 million on September 15, 2025, to develop and apply computational methods integrating metabolomic and genomic data to interrogate the pathogenesis of chronic obstructive pulmonary disease under the Cardiovascular Diseases Research program (CFDA 93.837). Performance runs through May 31, 2029, in Charlottesville, Virginia. The funded work centers on expanding and refining the MetaboxCan analytical method,...
- The National Heart, Lung, and Blood Institute awarded $1,137,435 to the University of Pennsylvania on March 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance therapeutic gene-editing approaches for cardiovascular and inherited disease. The recipient is developing and translating gene-editing therapies across three therapeutic domains. The first targets liver-centered, multiplex editing to prevent atherosclerotic cardiovascular disease through tunable...